share_log

Loctek Ergonomic Technology Corp. (SZSE:300729) Might Not Be As Mispriced As It Looks

Simply Wall St ·  Sep 28 22:16

When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 30x, you may consider Loctek Ergonomic Technology Corp. (SZSE:300729) as a highly attractive investment with its 13.9x P/E ratio. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly reduced P/E.

Recent times haven't been advantageous for Loctek Ergonomic Technology as its earnings have been falling quicker than most other companies. The P/E is probably low because investors think this poor earnings performance isn't going to improve at all. If you still like the company, you'd want its earnings trajectory to turn around before making any decisions. If not, then existing shareholders will probably struggle to get excited about the future direction of the share price.

big
SZSE:300729 Price to Earnings Ratio vs Industry September 29th 2024
If you'd like to see what analysts are forecasting going forward, you should check out our free report on Loctek Ergonomic Technology.

How Is Loctek Ergonomic Technology's Growth Trending?

There's an inherent assumption that a company should far underperform the market for P/E ratios like Loctek Ergonomic Technology's to be considered reasonable.

If we review the last year of earnings, dishearteningly the company's profits fell to the tune of 33%. That put a dampener on the good run it was having over the longer-term as its three-year EPS growth is still a noteworthy 11% in total. Accordingly, while they would have preferred to keep the run going, shareholders would be roughly satisfied with the medium-term rates of earnings growth.

Turning to the outlook, the next three years should generate growth of 18% per year as estimated by the five analysts watching the company. That's shaping up to be similar to the 19% each year growth forecast for the broader market.

With this information, we find it odd that Loctek Ergonomic Technology is trading at a P/E lower than the market. Apparently some shareholders are doubtful of the forecasts and have been accepting lower selling prices.

The Final Word

Using the price-to-earnings ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.

We've established that Loctek Ergonomic Technology currently trades on a lower than expected P/E since its forecast growth is in line with the wider market. There could be some unobserved threats to earnings preventing the P/E ratio from matching the outlook. It appears some are indeed anticipating earnings instability, because these conditions should normally provide more support to the share price.

Before you take the next step, you should know about the 3 warning signs for Loctek Ergonomic Technology (1 makes us a bit uncomfortable!) that we have uncovered.

You might be able to find a better investment than Loctek Ergonomic Technology. If you want a selection of possible candidates, check out this free list of interesting companies that trade on a low P/E (but have proven they can grow earnings).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment